Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
03 Marzo 2023 - 3:01PM
Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage
pharmaceutical company developing transformative therapies for
people suffering from diseases with high unmet medical needs, today
announced that the Company will participate in two upcoming
investor conferences in March:
- 43rd Annual TD Cowen Health
Care Conference: Adrian Adams, Chairman and Chief
Executive Officer, will participate in a fireside chat on
Wednesday, March 8, 2023 at 11:10 a.m. ET in Boston, MA.
- 2nd Annual Needham Virtual
Neuroscience Forum: Adrian Adams, Chairman and Chief
Executive Officer, will participate in a fireside chat on
Wednesday, March 15, 2023 at 3:20 p.m. ET.
A live webcast of each event will be available
on the Investors section of the Impel Pharmaceuticals website at
https://investors.impelpharma.com/. Replays of the presentations
will be available on the website for 90 days.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company
developing transformative therapies for people suffering from
diseases with high unmet medical needs. Impel offers treatments
that pair its proprietary POD® technology with
well-established therapeutics. In September 2021, Impel received
U.S. FDA approval for its first product, Trudhesa® nasal spray,
which is approved in the U.S. for the acute treatment of migraine
with or without aura in adults. In addition to Trudhesa, the
Company continues to address patient needs via licensing and
partnerships.
For additional information about Impel, please
visit www.ImpelPharma.com
Contact:
Media Relations:Melyssa
WeibleElixir Health Public RelationsPhone: (1)
386-366-0616Email: mweible@elixirhealthpr.com
Investor RelationsJanhavi MohiteStern Investor
RelationsPhone: 212-362-1200Email: janhavi.mohite@sternir.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Gráfica de Acción Histórica
De May 2023 a May 2024